XERS's Quality Score fell 1 point on Mon, Nov 9, to 22.
Follow XERS's news. Pro members can get an alert when Xeris Biopharma Holdings files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 50% from Nov 2 to Nov 6 while the S&P 500 fell 2%.
| Operating margin | Up 14.9 points on the year |
| Its score | Up:Highest Quality Score since Aug 2025 |
| Latest filing | 8-K, Nov 5 |
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +4.6% on average, higher 2 of 4 times.
An officer, Kevin McCulloch, sold 25,000 shares on Nov 5, under a planned sale. 29 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. XERS scores 22 today, against a median of 14.5 over its last 20 recorded sessions.
XERS is #1 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Share count against a year before: XERS +8.4%, RCUS +19%.
Expected to report Thu Mar 4, before the open (in 115 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $107.2M, 44% more than a year ago; a profit of $0.06 a share.
“The increase was primarily driven by increased patient demand for Recorlev.”
XERS's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | more than $1 billion |
“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”
From its results filing (SEC filing · Nov 5)
Sales grew 38% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 8.4% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +19.6% | +25.1% | not yet |
| Aug 6, 2026 | -11.3% | -9.3% | +4.7% |
| May 7, 2026 | +5.2% | +4.1% | +0.9% |
Sales grew every year from 2020 to 2025, to $292M. It turned a profit in 2025 after a loss in 2024.
RSI 82.4, MACD above signal, above both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: XERS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
“Our industry is characterized by intense competition and a strong emphasis on proprietary products.”
XERS scores 22 today, which Breakaway calls Exceptional. It is #1 of 281 in Biotech by Quality Score, with 9 of 14 chart checks firing. Up 50% from Nov 2 to Nov 6 while the S&P 500 fell 2%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
XERS scores 22 today, which Breakaway calls Exceptional (20 or more). That is #1 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind XERS's 22.
Expected to report Thu Mar 4, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. XERS closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.